We Can Help

The costs of mesothelioma can be overwhelming. They can include income loss, expensive treatments that may not be covered by health insurance, plus pain and suffering for you and for your family. Because the disease is preventable – and because it is usually caused by someone else’s negligence – legal options may be available to help regain these costs. Asbestos lawyers focus their practice on knowledgeably and effectively bringing to justice companies that exposed employees and the public to asbestos products. A mesothelioma attorney can help you consider your options and file a claim against the company responsible for your asbestos-related illness. More than one company may be responsible. A mesothelioma attorney identifies all companies at fault. Mesothelioma lawsuits have helped thousands of people receive financial assistance. A lawsuit can result in much-needed money to help reduce financial hardships during an illness and can also provide a more stable future for your loved ones. A lawyer specializing in asbestos litigation can help you seek compensation for expenses related to illness caused by asbestos exposure.

Tecentriq Raises Hope of New Mesothelioma Clinical Trial

The FDA recently approved immunotherapy drug Tecentriq (atezolizumab) for certain bladder and non-small cell lung cancers, raising hopes for a mesothelioma-specific clinical trial in 2017. Tecentriq, a product of Genentech Oncology, is following the path of Keytruda (pembrolizumab) and Opdivo (nivolumab) as drugs that target a specific protein blocking a body’s immune system from attacking…

The post Tecentriq Raises Hope of New Mesothelioma Clinical Trial appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

[…]

Using Keytruda for Mesothelioma May Become a Reality

The U.S. Food and Drug Administration recently upgraded its approval of pembrolizumab (Keytruda) for metastatic non-small cell lung cancer, inching it closer to becoming an accepted treatment option for pleural mesothelioma. Pembrolizumab, produced by pharmaceutical giant Merck & Co., also is marketed as Keytruda. The FDA’s announcement last week converted its previous “accelerated” approval in…

The post Using Keytruda for Mesothelioma May Become a Reality appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

[…]

FDA Speeds Possible Second-Line Treatment for Mesothelioma

The U.S. Food and Drug Administration awarded Fast Track designation recently to the WT1 cancer vaccine, moving it closer to becoming the first approved second-line treatment for malignant pleural mesothelioma. The vaccine, also known as galinpepimut-S, is an immunotherapy agent that targets the WT1 protein, which is expressed in high levels in various cancers, such…

The post FDA Speeds Possible Second-Line Treatment for Mesothelioma appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

[…]

Immunotherapy Trial for Mesothelioma Shows Early Promise

The immunotherapy drug avelumab showed promising results in a recent phase I clinical trial for malignant mesothelioma, raising hopes as a future second-line therapy. The clinical trial included 53 patients with pleural or peritoneal mesothelioma. It was part of the JAVELIN development program for avelumab, a series of clinical studies testing the drug on about…

The post Immunotherapy Trial for Mesothelioma Shows Early Promise appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

[…]